Bromantane (N-(4-bromophenyl)adamantan-2-amine) is an atypical psychostimulant and anxiolytic with an adamantane scaffold. Unlike classical stimulants, it does not deplete neurotransmitter reserves but activates their synthesis de novo via genomic mechanisms.
Mechanism of Action
The primary mechanism is indirect genomic activation of dopamine synthesis. A single dose produces a 2–2.5-fold upregulation of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (DOPA-decarboxylase) in rat hypothalamus within 1.5–2 hours post-administration. TH is the rate-limiting step of dopamine biosynthesis: L-tyrosine → L-DOPA. Increased DA synthesis and release correlates with upregulation of both enzymes in the hypothalamus, striatum, VTA, and nucleus accumbens. The precise molecular trigger for transcriptional activation remains unknown; PKA and particularly PKC activation have been identified as mediators of the pharmacological effects.
Additional Mechanisms
Bromantane enhances GABAergic neurotransmission upon both acute and chronic administration — reducing GABA reuptake and modulating GABA-A receptors, which fully eliminates the psychomotor agitation typical of classical stimulants. Direct monoamine reuptake inhibition (DAT IC₅₀ ≈ 3.56 μM in vitro) is possible but requires concentrations well above therapeutic levels and is likely clinically insignificant. Additionally upregulates BDNF and NGF in selected brain regions; reduces pro-inflammatory cytokines IL-6, IL-17, and IL-4.
Clinical Data
Multicenter study (728 asthenia patients, 28 days, 50–100 mg/day): CGI-S 76.0%, CGI-I 90.8%. Therapeutic effect persisted one month after discontinuation. Adverse effects in 3% of patients, none classified as serious; 0.8% discontinued treatment. No tolerance or dependence observed in long-term animal studies.
Storage
Powder stable for 3–5 years at +15°C…+25°C in airtight container protected from moisture and direct UV. DMSO or ethanol solutions: 3–6 months; oil-based preparations: 6–12 months at +2°C…+8°C.
BIOLABCHEMICALS